Text Size

Autologous Bone Marrow Stem Cells Transplantation in Patients With Temporal Lobe Epilepsy

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Jaderson Costa da Costa, Instituto do Cerebro de Brasilia
ClinicalTrials.gov Identifier:
NCT00916266
First received: April 24, 2009
Last updated: March 21, 2012
Last verified: March 2012
History of Changes
  Purpose

This research investigates the use of autologous bone marrow stem cells for the treatment of medically refractory temporal lobe epilepsy patients.


Condition Intervention Phase
Epilepsy
 Procedure: Stem cell transplantation
 Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase 1 Study of Autologous Bone Marrow Stem Cells Transplantation in Patients With Temporal Lobe Epilepsy

Resource links provided by NLM:

MedlinePlus related topics: Epilepsy Seizures
U.S. FDA Resources

Further study details as provided by Instituto do Cerebro de Brasilia:

Primary Outcome Measures:
  • seizure frequency [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • adverse effects [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
  • hippocampal volume [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
  • cognitive performance [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 20
Study Start Date: July 2008
Estimated Study Completion Date: December 2012
Estimated Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: stem cell transplantation
Patients with refractory temporal lobe epilepsy that are transplanted with autologous bone marrow stem cells in order to provide seizure control.
 Procedure: Stem cell transplantation
Transplantations with autologous bone marrow mononuclear stem cells by selective posterior cerebral artery angiography
Other Name: BMMSC - Bone Marrow Mononuclear Stem Cells

Detailed Description:

The aim of this study is to evaluate autologous bone marrow stem cells transplantation as a safe and potentially beneficial treatment for patients with temporal lobe refractory epilepsy. We are mainly evaluating seizure frequency, hippocampal volume an cognitive performance

  Eligibility

Ages Eligible for Study:   18 Years to 64 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • temporal lobe medically refractory epilepsy patients with hippocampal atrophy

Exclusion Criteria:

  • under 18 or over 65 years old patients
  • previous neurological surgery
  • other neurodegenerative diseases
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00916266

Locations
Brazil
Instituto do Cerebro
Porto Alegre, RS, Brazil
Sponsors and Collaborators
Instituto do Cerebro de Brasilia
Investigators
Principal Investigator: Jaderson C da Costa, MD, PhD Instituto do Cerebro de Brasilia
  More Information

No publications provided

Responsible Party: Jaderson Costa da Costa, MD, PhD, Instituto do Cerebro de Brasilia
ClinicalTrials.gov Identifier: NCT00916266     History of Changes
Other Study ID Numbers: Stem cells in Epilepsy
Study First Received: April 24, 2009
Last Updated: March 21, 2012
Health Authority: Brazil: National Committee of Ethics in Research

Keywords provided by Instituto do Cerebro de Brasilia:
Seizure frequency
Hippocampal volume
Adverse effects

Additional relevant MeSH terms:
Epilepsy
Epilepsy, Temporal Lobe
Brain Diseases
 Central Nervous System Diseases
Nervous System Diseases
Epilepsies, Partial

ClinicalTrials.gov processed this record on June 18, 2013